409 results about "Mrna expression" patented technology

The present invention discloses a strain of Lactobacillus paracasei that simultaneously activates immune regulation and antioxidant pathways to alleviate vaginitis, belonging to the field of microbial technology. The present invention screened and obtained a strain of Lactobacillus paracasei CCFM1316, which has the effect of repairing related symptoms such as immune disorders and oxidative damage caused by vaginitis, specifically embodied in: reducing cellular NF-κB mRNA expression and cell supernatant IL-1β content, improving mouse vaginal immune response, enhancing mouse vaginal antioxidant capacity, improving mouse vaginal pathological manifestations and reducing pathogenic bacteria load. It reduces the mouse vaginal Gardnerella load and improves mouse vaginal pathological manifestations; therefore, Lactobacillus paracasei CCFM1316 has great application prospects in products that improve and repair immune disorders and oxidative damage problems caused by vaginitis.

The invention provides application of a P8 gene, or a P8 gene coding protein, or a recombinant vector or host bacteria containing a P8 gene coding region in improvement of GFP (Green Fluorescent Protein) expression quantity and / or inhibition of degradation of an mRNA (Messenger Ribonucleic Acid) attenuated substrate taking GFP as a reporter gene. The research finds that the P8 has a silence inhibition function, can inhibit degradation of a nonsense mediated mRNA decay substrate taking GFP as a reporter gene and degradation of an endogenous nonsense mediated mRNA decay (NMD) substrate of arabidopsis thaliana, can improve the mRNA expression quantity of AT1G0106020, RPS6, SMG7, AT5G35490, AT5G64430, AT1G36730, AT4G3900 and AT5G22570, and can reduce the expression quantity of AT1G72450 and AT2G400, and the research result lays a foundation for clarification of the function of the P8.

The invention relates to the technical field of RNA interference, and particularly discloses an RNA interference fragment of a crustacean hyperglycemia hormone gene and application of the RNA interference fragment. The RNA interference fragment provided by the invention is injected into a third step foot of a river crab in an injection manner and is used for interfering the mRNA expression quantity of a hyperglycemia hormone gene CHH of a crustacean of the river crab. The fighting behavior of the eriocheir sinensis is effectively controlled, the yield in large-scale breeding of the eriocheir sinensis is improved, and economic losses caused by incomplete crabs due to fighting of the eriocheir sinensis are reduced.

The invention discloses a 5 'UTR and application thereof. A nucleotide sequence of the 5' UTR is selected from a sequence shown in any one of SEQ ID NO.1-6. The 5 'UTR can prolong expression and stability of mRNA (messenger ribonucleic acid) and remarkably improve the immune effect of a vaccine.

The invention provides application of an Aars1 gene in regulation and control of expression of an exogenous recombinant protein, and belongs to the technical fields of recombinant protein expression, gene engineering and cell culture. According to the CHO cell line, shRNA fragments of targeted Aars1 genes are inserted and integrated into piggyBac transposon vectors, a recombinant vector for inhibiting / silencing the Aars1 genes and an Aars1 low-expression CHO cell line are constructed, the CHO cell line can remarkably reduce the mRNA expression level of the Aars1, meanwhile, the CHO cell line serves as a host cell for recombinant protein expression, and compared with a wild type CHO cell line, the CHO cell line has the advantages that the expression level of the CHO cell line is greatly improved; the recombinant adalimumab can improve the expression quantity of recombinant protein (the expression quantity of the recombinant adalimumab is increased by 3.1 + / -0.18 times), effectively overcomes the problem of low expression level of the existing CHO cell expression system, and can be used for further constructing a recombinant protein expression system or kit.

The invention discloses a grape seed source anti-inflammatory peptide, and belongs to the technical field of biological medicine. The amino acid sequence of the anti-inflammatory peptide is selected from any one of WGF, SHFGF, EGPFF, WAPR, SFYRAF, HFAFL, PGRF or FDSF. A BPS-induced RAW 264.7 mouse mononuclear macrophage inflammation model is established, and the eight synthetic peptides are found to significantly reduce the content level of NO in inflammatory cells and have an inhibition effect on secretion of inflammatory factors TNF-alpha and IL-6. A qRT-PCR (quantitative reverse transcription-polymerase chain reaction) experiment shows that the synthetic peptide can inhibit expression of mRNA (messenger Ribonucleic Acid) of p65, Tnf alpha, Il6, Il1b and Nos2, and can play an anti-inflammatory role by regulating and controlling an NF-kappa B signal channel. According to the method, the high-activity anti-inflammatory peptide is screened from the wine brewing byproduct grape seeds for the first time, and green and high-value utilization of the grape processing byproduct is realized.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention discloses an application of isorhamnetin in preparation of an anti-myocardial fibrosis medicine, and belongs to the technical field of medicines. The invention proposes that the isorhamnetin can effectively reduce myocardial tissue collagen deposition for the first time, and the medical application of the isorhamnetin is expanded. The isorhamnetin is used as the anti-myocardial fibrosis medicine, can effectively relieve the increase of mRNA expression levels of alpha-SMA, COL-1, COL-3, p53, PAI-1, IL-1beta and IL-6, and has the function of retarding myocardial fibrosis. The isorhamnetin is used as the active component of the anti-myocardial fibrosis medicine, the safety is high, the side effect is small, a novel anti-myocardial fibrosis treatment strategy is provided, and the application blank of the isorhamnetin in the field is filled.

The invention belongs to the technical field of biological genetic engineering, and relates to a high-risk myelodysplastic syndrome screening gene and a diagnostic kit thereof. The invention provides an application of detecting YTHDF2, METTL3 and NAT10 gene expression of bone marrow cells of high-risk MDS patients as a specific molecular marker for screening the high-risk myelodysplastic syndrome, and by detecting mRNA expression levels of the YTHDF2, METTL3 and NAT10 genes, the screening of the patients in the high-risk myelodysplastic syndrome is facilitated. Meanwhile, treatment and prognosis evaluation of patients with high-risk myelodysplastic syndromes can be better guided. Only the bone marrow fluid of the patient needs to be extracted and collected during bone marrow cytology examination of the patient, the patient compliance is good, the bone marrow fluid is selected from human bone marrow fluid mononuclear cells, the detection result is more accurate, and the method is suitable for clinical large-scale application.

The present invention provides a method for computer analysis of a genome of a plant subject, comprising identifying a plurality of sequences that collectively define a promoter set of the plant subject, where each sequence within the promoter set consists of an expression control region, the expression control region extends from an initiation codon of an open reading frame to about 100 kilobases away from the 5'and / or 3 'end of the initiation codon. A transcriptome in the form of mRNA expression data of a plant subject is obtained and analyzed using a sequence-based modeling algorithm to provide a predicted value of the expression level of each protein coding gene within the transcriptome and associate this value with the sequence of the corresponding expression control region within the promoter group. The method can be used to generate new designs for expression control sequences, which are most likely to provide the desired expression profile for operably linked coding sequences. Nucleic acid libraries, plant cells, plant tissues and plants comprising the novel expression control sequences are also provided.

The invention discloses application of LW6 in preparation of drugs for preventing and treating neuroinflammation and protecting microglial cells. Cell experiments prove that the LW6 can inhibit the expression of HIF-1alpha protein in LPS-induced microglial cells BV2, can inhibit the mRNA expression level of inflammatory factors IL-1beta and IL-6 in the microglial cells BV2, and can inhibit the mRNA expression level of microglial cell inflammatory enzyme iNOS, which indicates that the LW6 can protect the microglial cells and prevent and treat neuroinflammation, and has a significant effect on degenerative diseases such as Alzheimer's disease. The compound has certain significance in treating Parkinson's disease, and can be used for preparing medicines for preventing and treating neuroinflammation and medicines for protecting microglial cells.

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention discloses a molecular chaperone synergistic blue-copper peptide and application thereof, belongs to the technical field of skin care, and particularly relates to a blue-copper peptide composition formed by compounding blue-copper peptide and N-acetylneuraminic acid, and the structure of the blue-copper peptide is that copper is connected to glycyl-L-histidyl-L-lysine; the blue copper peptide and the N-acetylneuraminic acid are mixed according to the mass ratio of 1: (0.1-1) for use, and further, phenylalanine derivatives can be added into the mixture for compounding. When the blue copper peptide composition obtained by the invention is applied to cells, the cell survival rate is high, the non-enzymatic glycosylation inhibition rate is good, and the expression of Elastin, Col-I and Col-IV mRNA in the cells is high. Therefore, the blue copper peptide composition disclosed by the invention is high in cell survival rate, good in non-enzymatic glycosylation inhibition rate and capable of improving the mRNA expression of Elastin, Col-I and Col-IV in cells, and the application of the blue copper peptide composition.

The invention discloses application of plant-derived glyceroglycolipid in preparation of an anti-inflammatory product, inflammation is RAW264.7 cell inflammatory response induced by LPS (lipopolysaccharide), and the plant-derived glyceroglycolipid can resist inflammation by inhibiting expression of inflammatory factors. By combining column chromatography with chromatographic analysis, efficient extraction, precise separation and structural identification of the plant GL are realized, and important technical support is provided for research of plant lipids. The plant GL can significantly inhibit inflammatory response of RAW264.7 macrophages, including reduction of LPS-induced cellular morphological change, down-regulation of inflammatory factor mRNA expression and reduction of CD86 expression level. The invention provides a solid molecular level theoretical basis for the application of the plant glycerol glycolipid in the development of anti-inflammatory functional foods and medicines.

Provided herein are, inter alia, agents (e.g., RNAi agents, dsRNA agents) comprising a sense strand and an antisense strand targeting CIDEB (e.g., hCIDEB); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the agents (e.g., RNAi agents, dsRNA agents) including, e.g., methods of inhibiting or decreasing CIDEB expression (e.g., mRNA expression), methods of treating CIDEB associated diseases, and methods of treating liver diseases (e.g., MASH).

The present invention discloses the use of 3,4-dihydropsoralen in the preparation of a drug for preventing or treating rheumatoid arthritis. The present invention simulates RA by constructing TNF-a-induced SW982 cells. The results show that 3,4-dihydropsoralen (DP) can downregulate the mRNA expression of inflammatory factors, chemokines, and matrix degrading enzymes through the IL-17 signaling pathway, and affect the IL-17 signaling pathway and the NF-κB signaling pathway to jointly exert an anti-inflammatory effect, thereby effectively improving rheumatoid arthritis. This provides a theoretical basis for the application of 3,4-dihydropsoralen in the clinical treatment of rheumatoid arthritis and opens up new therapeutic drugs and approaches.

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The invention relates to the technical field of biological medicine, and provides application of TRIM69 in preparation of a kit for auxiliary diagnosis of systemic lupus erythematosus. The kit assists in diagnosing systemic lupus erythematosus by detecting the TRIM69 level. Through the mRNA expression quantity of the TRIM69 and the expression quantity and / or concentration of the protein, the auxiliary diagnosis of the systemic lupus erythematosus is realized, and the TRIM69 as a biomarker has important values in the aspects of auxiliary diagnosis, disease activity monitoring, prognosis evaluation, diagnosis efficiency improvement and the like. Not only can a doctor be helped to recognize a high-risk patient earlier, but also a basis can be provided for individualized treatment, so that the long-term prognosis of the systemic lupus erythematosus patient is improved.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of Xianglian intestine decoction in preparation of a medicine for treating ulcerative colitis through a targeted TLR4 / NLRP3 / GSDMD channel. According to the invention, the TLR4 is determined as a key target, and experiments show that the active ingredients in the Xianglian intestine soup and the TLR4 have very strong binding affinity. In-vivo experiments prove that the Xianglian intestine soup down regulates the protein levels of TLR4, NLRP3 and GSDMD-N and the mRNA expression (Plt; 0.05) of IL-1beta and IL-18, so that the pyroptosis is inhibited. Furthermore, the Xianglian intestine decoction inhibits NLRP3 inflammasome activation and GSDMD-mediated pyroptosis by targeting TLR4 so as to relieve UC inflammation and intestinal barrier injury. The invention provides a mechanism insight for the clinical curative effect of the Xianglian intestine decoction for treating ulcerative colitis.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The invention relates to the field of in-vitro transcription, in particular to a 5 'UTR element, an expression vector and application of the 5' UTR element. The present invention provides a 5 'UTR element having: a nucleotide sequence as shown in any of SEQ ID NO: 9 to SEQ ID NO: 12; or a nucleotide sequence which is obtained by substituting, deleting or adding one or more basic groups to the nucleotide sequence as shown in the specification, and has the same or similar function as the nucleotide sequence as shown in the specification; or a nucleotide sequence having at least 80% of identity with the nucleotide sequence shown in the description. By providing the 5 'UTR sequence, the problem that when mRNA is synthesized in vitro, the prokaryote 5' UTR sequence cannot have the functions of high mRNA expression efficiency and high mRNA capping efficiency at the same time is solved.

The invention discloses an anti-inflammatory CAR-macrophage targeting FAP, a preparation method thereof and application of the anti-inflammatory CAR-macrophage in preparation of drugs for treating fibrosis diseases, and belongs to the technical field of biological medicines. The invention provides an FAP-specific chimeric antigen receptor, an mRNA expression vector of the FAP-specific chimeric antigen receptor, a His-labeled STING signal channel inhibitor and an mRNA expression vector of the His-labeled STING signal channel inhibitor. In-vivo and in-vitro macrophage editing can be effectively realized by delivering CAR mRNA and TRIM13mNRA through LNP, the ability of targeted phagocytosis of FAP positive cells is endowed, meanwhile, anti-inflammatory phenotypic polarization of macrophages is promoted, local inflammation is improved, and fibrosis progress driven by inflammation is synergistically restrained.

The invention provides a plant lactobacillus KSFY202407 capable of resisting fatigue and improving athletic ability and application of the plant lactobacillus KSFY202407, and belongs to the technical field of microorganisms. The preservation number of the plant lactobacillus KSFY202407 provided by the invention is CGMCC No.31104. The strain can maintain stable increase of mouse weight, prolong exhaustive running and exhaustive swimming time, reduce blood lactic acid concentration after excessive exercise, improve the content of muscle glycogen and hepatic glycogen in gastrocnemius muscle, reduce serum creatine kinase and blood urea nitrogen concentration, and improve the immunity of mice. The obvious effect of up-regulating the mRNA expression levels of AMPK, PGC1-alpha, SOD2 and GPx1 is achieved. It is shown that the KSFY202407 can improve exercise tolerance, relieve exercise-induced fatigue and promote exercise ability, and a candidate strain is provided for development of exercise-related products.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for improving ovarian development and a preparation method and application thereof. The reagent for improving ovarian development is prepared by mixing the following raw materials in parts by weight: 20-30 parts of N-acetylcysteine; 5 to 10 parts of tranexamic acid; 3 to 8 parts of creatine; and 3000 parts of water. According to the reagent, the mRNA expression of PKD1P6 and follicle stimulating hormone receptors (FSHR) in ovarian tissues is up-regulated, the activity and functions of cumulus granular cells are enhanced, and apoptosis of the cumulus granular cells is inhibited, so that the effects of effectively promoting follicle development and inhibiting the apoptosis of the cumulus granular cells are achieved.

The present invention relates to the field of molecular biology, and in particular to an SLC17A5 gene inhibitor and a use thereof. The present invention provides a use of the SLC17A5 gene inhibitor in preparation of a kidney cancer treatment product. According to the SLC17A5 gene inhibitor provided by the present invention, a proper RNAi target sequence and oligo DNA double-stranded sequence are designed for a target gene, and a lentiviral vector plasmid containing the oligo DNA double-stranded sequence and a finally formed lentivirus are constructed; the resistance gene carried in the lentivirus can effectively reduce the mRNA expression of the target gene SLC17A5, and the lentivirus has an very obvious knockdown effect, has high inhibitory efficiency on cell proliferation and cell migration of kidney cancer cells, and can be used in drugs for treating kidney cancer; moreover, the present invention can be operated with high throughput and has high repeatability.

The invention discloses a preparation method of prune exosomes and application of the prune exosomes in regulation and control of pigment metabolism and skin cell inflammatory response, and the preparation method comprises the following steps: taking prune, washing, peeling, dicing, juicing, adding a compound enzyme preparation, centrifuging at 2,000 g for 20 min, carrying out trehalose-assisted ultracentrifugation, centrifuging at 12,000 g for 30 min, centrifuging at 40,000 g for 60 min, centrifuging at 120,000 g for 70 min, collecting precipitate PBS, re-suspending, and filtering to obtain the high-purity prune exosomes. It is proved for the first time that the prune exosome dose-dependently inhibits the melanin content and tyrosinase activity in B16F10 melanoma cells, the mRNA expression level of key inflammatory factors TNF-alpha, IL-1beta and IL-6 in TNF-alpha-induced Hacat cells is remarkably reduced, in addition, the inhibition effect of melanin can be amplified through an STAT3 channel by combining the prune exosome with luteolin, and the application of the prune exosome to the preparation of the anti-inflammatory drug is promoted. The polypeptide can be used for preparing a preparation for regulating pigment anabolism and skin-related inflammatory response, and a potential biological application value is exerted.

The invention belongs to the technical field of microorganisms, and particularly relates to application of a staphylococcus epidermidis H62-3 viable bacterium preparation in preparation of a medicine for preventing or treating psoriasis. Experimental results show that the staphylococcus epidermidis H62-3 viable bacterium preparation improves skin erythema and scale symptoms of a psoriasis mouse model, remarkably reduces the skin lesion thickness, reduces the mRNA expression level of cytokines related to psoriasis at the skin lesion position of the psoriasis mouse model, and improves the psoriasis resistance of the psoriasis mouse model. And the cell factors comprise interleukin-17A, interleukin-17F and interleukin-23. The invention also discloses a preparation method of the cell factor. Therefore, the staphylococcus epidermidis H62-3 viable bacterium preparation has the prospect of being developed into the medicine for preventing or treating psoriasis.

A polypeptide complex, a protein, a nucleic acid, a composition and uses thereof. A cell specific high expression and long retention (ePR) strategy is employed to overexpress specific mRNA in hepatic stellate cells into therapeutic proteins and to promote long-term anchoring of the therapeutic proteins in a fibrotic matrix microenvironment. The first-generation and second-generation retinol derivatives containing carboxyl are determined, can partially replace cholesterol in lipoid nanoparticles (LNP), and are enriched in a fibrosis area through intravenous injection, so that the expression of mRNA in a fibrosis liver is improved by about 10 times. Furthermore, therapeutic mRNA has been engineered by coupling the gene sequence of the collagen binding domain (CBD) to the C-terminus of the therapeutic protein. In screening, it is found that the peptide sequence of placental growth factor (PLGF) shows the strongest collagen affinity, the liver residence time of overexpressed therapeutic protein can be prolonged, and systemic side effects are reduced to the minimum.

The present invention discloses a targeted knockout bovine FGFR1 The application of the sgRNA of the gene in constructing a bovine mammary epithelial cell line, wherein the sgRNA nucleotide sequence is shown in SEQ ID NO: 1. The mammary epithelial cell line obtained by constructing the sgRNA of the present invention through CRISPR / Cas9 technology, FGFR1 Protein expression was significantly downregulated, and knockout FGFR1 The gene expression had no significant effect on the viability and proliferation of mammary epithelial cells. PCNA 、 Cyclin D1 、 Cyclin E1 There was no significant change in the mRNA expression of the genes related to milk protein synthesis (such as CSN1S1 、 CSN2 、 CSN3 、 EFL5 ), lactose synthesis-related genes ( GLUT1 and HKⅡ ) and milk fat synthesis-related genes ( SCD‑1 ) were significantly decreased, providing a basis for in-depth analysis FGFR1 It provides key tools for the regulatory mechanisms of mammary epithelial cell proliferation, lactation synthesis and other biological behaviors.

The invention discloses antisense oligonucleotides for reducing XDH gene expression in a targeted manner and application of the antisense oligonucleotides, and belongs to the technical field of biological medicines. The antisense oligonucleotide mediates the degradation of the target mRNA through an RNase H (RNase H) dependent cleavage mechanism, and the mRNA expression of the XDH gene is horizontally knocked down after transcription; the antisense oligonucleotide molecule has a specific nucleic acid sequence, is combined with chemical modification design, can specifically bind XDH mRNA molecules in a targeting manner, promote XDH mRNA degradation and inhibit XDH protein synthesis, so that the expression level of XDH in cells is reduced, uric acid synthesis is reduced, the purpose of reducing uric acid is finally achieved, and cell experiments and animal model tests show that the antisense oligonucleotide molecule has a good application prospect. The antisense oligonucleotide molecule disclosed by the invention has a good uric acid reducing effect, and is long in drug effect duration and high in drug safety.